30 Nisan 2010 Cuma

Abilify Tabletten

Usage:
Schizophrenia: The recommended initial dose regardless of Abilify'ın meals on time as a single daily dose of 10 or 15 mg / day 'Roll. Maintenance dose is 15 mg / day. In clinical studies, 10-30 mg / day was assumed to be in the range of effective doses. Bipolar Mania: Meal should be independent of time as a single daily dose, initial dose usually 15 or 30 mg per day. If necessary, dose adjustment should be made in less than 24 hours. Antimanic efficacy (3-12 weeks) 15-30 mg / day dose has been proven in clinical studies for a series. 30 mg / day dose of fame on the reliability of clinical trials have not been evaluated. Abilify'nın safety and efficacy in patients under 18 years have not been established. CYP3A4 or CYP2D6 inhibitors Aripiprazolün with a strong commitment in the case at the same time should be the usual dose of aripiprazole dose reduced by half. Combined treatment ended, the aripiprazole dose should be raised again. A strong CYP3A4 inducer is added to aripiprazole therapy, aripiprazole dose should be doubled. CYP3A4 inducer is withdrawn aripiprazole dose should be reduced by combination therapy. CYP3A4 and CYP2D6 enzyme inhibitors, many patients are treated at the same time reducing the daily dose should be taken into account.

Indications:
indicated in the treatment of acute schizophrenic episodes of clinical improvement during continuation and maintenance treatment. Acute manic episodes associated with bipolar disorder when treatment was indicated.

Contraindications:
Or are hypersensitive to any component of aripiprazole in patients with contraindicated.

Notes:
can improve the clinical condition of patients several days to several weeks. Patients should be monitored closely during this time. should the possibility of suicide in psychotic disorders is, of course, as well as drug treatment, patients are closely monitored. Antipsychotics increase the risk of tardive dyskinesia after prolonged treatment, because when you see the signs and symptoms of tardive dyskinesia dose reduction or discontinuation of the drug are considered. These findings may or may worsen temporarily following discontinuation of treatment. Antipsychotics, including aripiprazole, sometimes in conjunction with the implementation of Neuroleptic Malignant Syndrome (NMS), a finding called The complex has been reported to potentially fatal. Clinical symptoms of NMS hyperpyrexia muscle tension, mental status changes and autonomic instability are signs (irregular pulse or blood pressure, tachycardia, excessive sweating, and heart rhythm disturbances). Fosfokinazda increase can also occur creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure as well. If a patient signs and symptoms of NMS, NMS develop or without other clinical symptoms of fever, if medicine should be discontinued immediately. History of seizure disorder or condition associated with seizures, caution should be used in patients. Alpha1-adrenergic receptor antagonist activity as potential reasons can be brought aripiprazole with orthostatic hypotension. Aripiprazole cardiovascular diseases (myocardial infarction or ischemic heart disease, history, heart failure or conduction abnormalities), cerebrovascular disease, or hypotension may lead to conditions (dehydration, hypovolemia and antihypertensive drug treatment) announced that patients should be used with caution. Aripiprazole, core body temperature rises, such that intense exercise can lead to excessive heat, anticholinergic effect, which would simultaneously with the removal of water intake or exposure conditions such as these for the appropriate patient care by showing that prescriptions should be. been striving with antipsychotic use and esophageal cancer link brought dismotilitesi. Aspiration should be used with caution in patients with increased risk. Treated with atypical antipsychotics, demansla associated with psychosis have a higher risk of death in elderly patients. Although various causes of death, cardiovascular death, a large proportion (eg heart failure, sudden death) or infectious (eg pneumonia) in nature are considered. Aripiprazole in the treatment of patients with psychosis associated demansla used. In the context of Alzheimer's disease in elderly patients with psychosis, including death, cerebrovascular events (eg stroke, transient ischemic attack) have been reported. Treated with aripiprazole in patients with cerebrovascular events as a statistically significant dose-response relationship. Hyperglycemia and diabetes have been reported in patients, in some cases, hyperglycemia and ketoacidosis is exaggerated, hyperosmolar coma or death has been reported, included. Hyperglycemia have been reported rarely. Background risk of diabetes mellitus in patients with schizophrenia is high and rising incidence of diabetes mellitus in the general population have atypical antipsychotic use and glucose abnormalities is difficult to evaluate the relationship between. hyperglycemia in patients can be treated with atypical antipsychotic drugs linked to the risk of side effects not be predicted exactly. Atypical antipsychotics and diabetes mellitus was should be monitored regularly in patients diagnosed begun against a possible worsening of glycemic control. The risk factors for diabetes mellitus (eg obesity, diabetes, family history) and atypical antipsychotic treatment of patients starting treatment and periodically during treatment at the start of the fasting blood sugar test should be performed. In some cases, anti-diabetic treatment despite discontinuation of the drug still has to be. Pregnancy Category C.. Given the limited experience in humans, the fetus during pregnancy only if the expected benefits should be used against the potential risk if more than. Pass into breast milk is unknown. Patients should be instructed to avoid when breast feeding are among aripiprazole. Reliability and effectiveness in patients below 18 years have not been established. Patients, careful not to obstruct, to aripiprazolün vehicles should be warned against, to use, including hazardous machinery.

Side Effects:
As seen in placebo-controlled trials of schizophrenic patients did, the treatment side / side effects: Very common (> 10%): headache, insomnia. Common (> 1% - <10%):> 10%): nausea, somnolence, akathisia. Common (> 1% - <10%):> 0.1% <1%): tachycardia, orthostatic hypotension. Known to be associated with antipsychotic treatment, and aripiprazole have been reported to be linked to adverse events among the rare neuroleptic malignant syndrome, tardive dyskinesia and seizure case reports are available. The study reported long term bipolar mania Side / side effects: irritability, tremors, and akathisia. Market Report Post reported Side / side effects: Very rare (<0.01%), syncope, alanine aminotransferase values increased, increased levels of aspartate aminotransferase, GGT increased, pancreatitis, body temperature, balance disorder (eg hypothermia, fever), allergic reaction (ör . anafilaktik reaction, angioedema, itching or hives), hyperglycemia, diabetes mellitus, elevated creatine phosphokinase, rhabdomyolysis, and priapism.

Drug Interactions:
FAQ Aripiprazolün impact on the primary consideration, when the central effects when they should be carefully taken with alcohol or other drugs. Aripiprazole, because some of the alpha1-adrenergic receptor antagonist antihypertensive agents akvitesi have the potential to increase the effect. Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. CYP3A4 inducers (eg carbamazepine) increase in aripiprazole clearance and can cause a decrease in plasma levels. CYP3A4 (eg ketoconazole) and CYP2D6 (eg quinidine, fluoxetine, paroxetine treatment) inhibit aripiprazole elimination and may increase the plasma levels. Aripiprazolün with ketoconazole and implementation, and the active metabolite of aripiprazole AUC 63% and 77% increases or ketoconazole with aripiprazole should be used and when, aripiprazole dose should be reduced to half the normal dose. Other strong CYP3A4 inhibitors (itraconazole) is expected to show similar effects and similar dose reduction should be applied, much weaker inhibitors (erythromycin, grapefruit juice) have not been investigated. CYP3A4 inhibitor combination therapy, the aripiprazole dose should be increased by the withdrawal. With a strong CYP2D6 inhibitor quinidine as the result of the implementation, aripiprazolün AUC increased by 112%, but returned to the active metabolite of 35% dehidro-aripiprazolün AUC. Time to implement and quinidine with aripiprazole, aripiprazole dose should be reduced to half the normal dose. Other strengths, such as paroxetine and CYP2D6 Fluoksatin inhibitörlerininde be expected should show similar effects and similar dose reduction should be applied. CYP2D6 inhibitor combination therapy, the aripiprazole dose should be increased by the withdrawal. given with a strong CYP3A4 inducer carbamazepine as a result, aripiprazolün and its active metabolite Cmax and AUC values dehidro-aripiprazolün decreased by about 70%. Carbamazepine therapy is added to aripiprazole dose should be two-fold increased. Further dose escalation based on clinical evaluation should be done. Combination therapy with carbamazepine should be reduced, the aripiprazole dose from the withdrawal.

Hiç yorum yok:

Yorum Gönder